Felodipine
As of the edition of 20 October 2026, Felodipine is a small molecule: marketed, first approved in 1988 (CH); acts on CACNA1C, CACNA1D and CACNA1F and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1993
- Kind
- Small molecule
- Brand name
- Plendil
- First approved
- 30 June 1988 (CH)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- AstraZeneca; 4 holders in all
- Registered trials
- 11, 0 stopped early
- Disease areas
- Heart and blood vessels; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Felodipine.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1F | Voltage-dependent L-type calcium channel subunit alpha-1F | O60840 |
| NR3C2 | Mineralocorticoid receptor | P08235 |
| CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Q01668 |
| CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Q13698 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Q13936 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 4 | 5 | 4 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant | 1991 to now |
| AstraZeneca | Applicant, Acquired holder and Lead sponsor of trials | 1994 to now |